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Summary A recent study showed an association between a single base substitution, T-*C, in the promotor region of the CYP17gene, the
risk of breast cancer and age at menarche in Asian, African-American and Latino women from California and Hawaii. The C allele was
associated with increased risk of breast cancer, significantly so for patients presenting with advanced disease, whereas the TT genotype was
associated with laterage at menarche in control subjects. We attempted to confirm these findings in a large case-control study in East Anglia,
England (835 cases and 591 control subjects). We found no evidence of an increased risk of breast cancer [odds ratio (OR) 1.10, confidence
interval (Cl) 0.89-1.37] or advanced breast cancer (OR 0.88, Cl 0.38-2.01) in C allele carriers, nor any association between age at menarche
and genotype. We conclude that these alleles do not significantly alter breast cancer risk in the English population.
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Epidemiological and laboratory studies indicate that breast cancer
risk is strongly related to hormonal factors, specifically exposure
to endogenous oestrogens. Ecological studies indicate that
hormone levels are strongly influenced by lifestyle factors (e.g.
diet), but genetic factors could also be important. This raises the
possibility that polymorphisms in genes involved in sex steroid
hormone metabolism may have a role in breast cancer suscepti-
bility. One such gene is CYPI7, which encodes an enzyme,
cytochrome P450cl7a. This enzyme has two different roles in
steroid interconversion: the 17ax hydroxylase activity can convert
progesterone to 17a-hydroxyprogesterone, and the 17,20 lyase
function may further convert 17a-hydroxyprogesterone to
androstenedione (the precursor ofboth oestrone and testosterone).
There is a polymorphic T to C substitution 34 bp upstream of the
translation initiation site in the promotor region ofthe gene, which
creates an MspAl restriction site (Carey et al, 1997). This substi-
tution also creates a fifth SpI-type (CCACC) motifin the 5'region
ofthe CYPI7gene. It is thought that gene transcription may corre-
late with the numberofthese motifs, and so this polymorphism has
the potential to alter the promotor activity and possibly also the
production rate of CYPI7.
Two association studies using this CYP17 MspAl restriction
fragment length polymorphism (RFLP) have been published to
date. One study investigated the association between genotype and
polycystic ovary and male pattern baldness (Carey et al, 1997).
Carriers ofthe C allele were found to have atwofold increased risk
of either polycystic ovary disease or male pattern baldness,
depending on sex. More recently, Feigelson et al (1997) reported
an association of the same C (A2) allele with an increased risk of
breast cancer, which was significant only in patients presenting
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with advanced breast cancer. They also found that within their
control group the TT (Al) homozygotes had a later age at
menarche than carriers of the C allele and they suggested that the
reduced risk ofbreast cancer associated with later age at menarche
is limited to TT homozygous women. However, this study was
performed using only 174 breast cancer cases and 285 control
subjects from three different ethnic groups and significant results
were only demonstrated in subgroup analyses. We set out to
confirm these findings in a much larger case-control study from
the East Anglian region ofEngland.
MATERIALS AND METHODS
Case and control subject selection
Cases were taken from a population-based study of breast cancer.
All women in the region served by the Anglian cancer registry
with breast cancer diagnosed between 1 January 1991 and 30 June
1996 who were under the age of 55 at diagnosis were eligible to
take part. Genotyping was carried out on the first 864 samples
received from 2007 eligible patients. Control subjects were
randomly selected from the UK part of the European Prospective
Investigation of Cancer (EPIC) (Riboli and Kaaks, 1997), a
prospective study ofdiet and cancer being carried out in the same
population from which the cases have been drawn. The EPIC
cohort comprises 25 000 individuals resident in Norfolk (East
Anglia), aged 45-74 years.
Genotype detection
The CYP17, 5'-utr, MspAl polymorphism assay has been
described previously (Carey et al, 1997; Feigelson et al, 1997).
Briefly, a 459-bp polymerase chain reaction (PCR) product was
amplified using the following primerpair: CYPI7-F, 5'-CATTCG-
CACCTCTGGAGTC and CYPJ7-R, 5'-GGCTCTTGGGGTAC-
TTG, and the following conditions on a TouchDown thermal
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Table 1 Genotype frequencies and associated breast cancer risks
Genotype Controls (n) Cases (n) Odds ratio 95% Cl
TT 229 303 1.00 0.81-1.24a
TC 277 402 1.09 0.86-1.36a
CC 85 130 1.17 0.92-1.49a
TC/CC 362 532 1.10 0.89-1.37
aFloated confidence interval (see text).
Table 2 Risk of breast cancer in women with late age at menarche
(2 13 years) by genotype
Genotype Adjusted ORa 95% Cl
All 0.94 0.71-1.26
TT 0.93 0.57-1.51
TC 0.95 0.61-1.46
CC 0.59 0.27-1.27
aAdjusted for age.
cycler (Hybaid, UK) with the use ofthe hot lid: 95°C, 20 min, one
cycle; 94°C, 1 min, 57°C, 1 min, 72'C, 1 min, 35 cycles; 72°C,
10 min, one cycle. The reaction was carried out in a50-gl volume,
using 50 ng of genomic DNA template, 200 gM dNTP, 3 mM
MgCl2, 200 nm of each primer, 0.6 U of Amplitaq Gold (Perkin
Elmer, UK) and 1 x Amplitaq Gold buffer. MspAl (NEB) digests
were carried out in a 20-gl volume according to manufacturer's
instructions and separated on a 2% agarose gel (Gibco BRL).
Statistical analysis
The association between CYP17 alleles and breast cancer was
assessed using X2 tests. For the three-way comparison between
genotype and risk of breast cancer, variances were estimated by
treating odds ratios as floating absolute risks (Easton et al, 1991).
This approach yields floated standard errors and floated confi-
dence intervals. Although the method does not alter the relative
risk estimates, it reduces the variances attributed to the odds ratios
that are not defined as 1.00, and also reduces unwanted covariance
between them. This allows a valid comparison between the two
non-baseline groups. A logistic regression model was used to
assess a potential interaction between genotype, age at menarche
and the risk ofbreast cancer. In this analysis, age was adjusted in
5-year strata.
RESULTS
The results of genotyping our case-control series for the T to C
polymorphism are shown in Table 1. The genotype distribution
in control subjects was very close to that expected under
Hardy-Weinberg equilibrium. We detected no significant differ-
ences in either the allele frequencies (%2 = 0.85, 1 d.f., P = 0.35) or
the genotype distributions between breast cancer cases and the
control subjects (%2 = 0.86, 2 d.f., P = 0.65). Table 1 also shows the
genotype-specific relative risks of breast cancer as estimated by
the odds ratio (OR). No significant effect of genotype on age was
found in either control subjects or cases, and so unadjusted odds
ratios are presented. Cases were also divided into three subgroups
according to stage at diagnosis: stage I (n = 367), stage II (n = 411)
and stage III/IV (n = 24). Again no significant effects were found,
with the relative risks ofthe three types ofbreast cancer in women
carrying the C allele being 0.95 (0.73-1.24), 1.23 (0.98-1.54) and
0.88 (0.38-2.01) respectively.
No effectofgenotype on age atmenarche was found inthecontrol
population: the mean ages at menarche were 12.94 years
(12.74-13.14) in TT homozygous women, 12.96 (12.74-13.18) in
heterozygotes and 12.95 (12.56-13.34) in CC homozygotes (one-
way ANOVA, P = 0.77). In addition, there was no significant associ-
ationbetweengenotype andage atfirstfull-term pregnancy orparity.
The relative risks of breast cancer associated with late age at
menarche (. 13 years) stratified by genotype are shown in Table 2.
We found a non-significant reduction in breast cancer risk in indi-
viduals with late age at menarche. There was no difference in this
risk when stratified by genotype, a finding consistent with the lack
of association between genotype and age at menarche in control
subjects.
DISCUSSION
We found no significant effect of the CYPJ7 promotor T to C
substitution on breast cancerrisk in a large case-control study, nor
have we been able to confirm the previously reported association
between the CYPJ7 genotype and risk of advanced breast cancer:
Feigelson et al (1997) reported a significant association of the C
allele with advanced disease (OR 2.5, 95% CI 1.07-5.94), indi-
cating that diseaseprogression may be morerapid in carriers ofthe
C allele. In contrast, we found a reduced risk of advanced disease
in C allele carriers. However, the number of cases with advanced
disease in each study was small, the associated confidence inter-
vals are wide and there was no significant difference between the
two risk estimates (X2 = 3.00, P = 0.082). Combining the data from
the two studies gives an OR for advanced cancer in women
carrying the C allele of 1.57 (0.89-2.90), and so the data are
compatible with a small increase in risk of advanced cancer. A
larger study addressing the issue of cancer progression would be
required to confirm this.
Late age at menarche has been shown to be associated with a
reduced risk ofbreast cancer (Kelsey et al, 1993), and the results
ofthis study are consistent with this effect. Unlike Feigelson et al
(1997) we found no effect ofgenotype on age at menarche. In our
control subjects, mean age at menarche was 0.02 years (95% CI
- 0.30 to 0.27) earlier in TT homozygotes than in women carrying
a C (A2) allele, whereas Feigelson et al reported that the mean age
at menarche in TT (AlAl) women was 0.4 years later. From our
result we would not expect to find an effect ofgenotype on risk of
breast cancer associated with late age at menarche, and no such
effect was demonstrated.
Our study had an 80% power to detect a 1.3-fold increased risk
in C-allele carriers at a significance level of 5%, which is the
magnitude of the effect reported in the study by Feigelson et al
(1997). However, we failed to confirm their reported association
between CYPI7genotype, age at menarche and breast cancer risk.
There are several possible explanations for the difference between
our results and those ofFeigelson et al. The ethnic background of
the two study populations are different (the population of East
Anglia is close to 100% white), and, although the CYPI7genotype
distribution in East Anglia is similar to that of the American
control subjects, there is the potential for as yet unidentified
gene-gene interactions between CYP17 and genes that differ in
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frequency in the two populations. Alternatively, it is possible that
the T-C substitution is not in itself disease causing, but in some
populations is in linkage disequilibrium with another alteration
that is disease causing. Ifthis were true, then the association would
only be apparent in those populations. Another possible explana-
tion is that genotype effects are age specific, with a marked effect
only in older cases. Further studies ofolder cases would be needed
to address this possibility. The most likely explanation is that the
original study was small and the positive associations reported
were chance findings that have not been confirmed by a larger and
more powerful study.
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